XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.23.3

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2023
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES |
Schedule of revenues disaggregated by business operations and timing of revenue recognition | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Years Ended:
​ | ​ | September 30,
​ |  | 2023 |  | 2022
Research and development services (over-time) | ​ | $ | 421,585 | ​ | $ | 592,001
Clinical laboratory testing services (point-in-time) | ​ | ​ | 7,612,975 | ​ | ​ | 10,398,782
Clinical laboratory services (over-time) | ​ | ​ | 3,540,456 | ​ | ​ | 5,127,953
Product and authentication services (point-in-time): | ​ | ​ | ​ | ​ |  | ​
Supply chain | ​ | ​ | 827,603 | ​ |  | 887,061
Large Scale DNA Production | ​ | ​ | 653,015 | ​ | ​ | —
Asset marking | ​ | ​ | 311,809 | ​ |  | 534,594
MDx test kits and supplies | ​ | ​ | — | ​ | ​ | 628,286
Total | ​ | $ | 13,367,443 | ​ | $ | 18,168,677
Schedule of opening and closing contract balances | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | October 1, |  | September 30, |  | $
​ |  | Balance sheet classification |  | 2022 |  | 2023 |  | change
Contract liabilities |  | Deferred revenue | ​ | $ | 563,557 | ​ | $ | 270,435 | ​ | $ | 293,122
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | October 1, |  | September 30, |  | $
​ |  | Balance sheet classification |  | 2021 |  | 2022 |  | change
Contract liabilities | ​ | Deferred revenue | ​ | $ | 281,000 | ​ | $ | 563,557 | ​ | $ | (282,557)
Schedule of anti-dilutive securities not included computation of net loss per share | ​
​ | ​ | ​ | ​ | ​
​ |  | 2023 |  | 2022
Warrants | ​ | 5,220,588 | ​ | 7,313,963
Restricted Stock Units | ​ | 282,640 | ​ | —
Options | ​ | 2,204,237 |  | 1,063,055
​ | ​ | 7,707,465 |  | 8,377,018
Schedule of reconciliation of cash, cash equivalents and restricted cash to amounts shown in statement of cash flows | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | September 30,
​ | ​ | 2023 | ​ | 2022
Cash and cash equivalents | ​ | $ | 7,151,800 | ​ | $ | 15,215,285
Restricted cash | ​ |  | 750,000 | ​ |  | —
Total cash, cash equivalents and restricted cash | ​ | $ | 7,901,800 | ​ | $ | 15,215,285
Schedule of property, plant and equipment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30,
​ |  | 2023 |  | 2022
Lab equipment | ​ | $ | 4,069,175 | ​ | $ | 4,059,754
Vehicles | ​ | ​ | 56,471 | ​ | ​ | 108,361
Leasehold improvements | ​ | ​ | 124,825 | ​ |  | 124,825
Total | ​ | ​ | 4,250,471 | ​ |  | 4,292,940
Accumulated depreciation | ​ | ​ | 3,412,201 | ​ |  | 2,069,952
Property and equipment, net | ​ | $ | 838,270 | ​ | $ | 2,222,988

X
- Definition Tabular disclosure of the components of cash, cash equivalents and restricted cash and cash equivalents. + References No definition available. + Details
Name: | apdn_ScheduleOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | apdn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details
Name: | us-gaap_PropertyPlantAndEquipmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration